AT-103-ED

AT-103-ED is a novel, long-acting formulation of a phosphodiesterase type 5 (PDE5) inhibitor currently under development for the treatment of erectile dysfunction (ED). Developed by Athelas (specifically the pharmaceutical division or associated entities), this drug candidate is designed to provide a significantly extended duration of action compared to existing first-generation PDE5 inhibitors like sildenafil or vardenafil. By inhibiting the PDE5 enzyme, AT-103-ED prevents the degradation of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum, thereby facilitating vasodilation and promoting penile erection in response to sexual stimulation. The 'ED' suffix in the code name specifically denotes its primary indication for erectile dysfunction, distinguishing it from other potential applications of the AT-103 molecule.